Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2215-2226

  Jarvis, Ashley ^a   Allerston, Charles K ^b   Jia, Haiyan ^b,c   Herzog, Birger ^b,c   Garza Garcia, Acely ^d   Winfield, Natalie ^a   Ellard, Katie ^a   Aqil, Rehan ^a   Lynch, Rosemary ^a   Chapman, Chris ^a   Hartzoulakis, Basil ^a   Nally, James ^a   Stewart, Mark ^a   Cheng, Lili ^b,c   Menon, Malini ^b,c   Tickner, Michelle ^b,c   Djordjevic, Snezana ^b   Driscoll, Paul C ^d   Zachary, Ian ^b   Selwood, David L ^e  

^a Domainex Ltd   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Ark Therapeutics Group plc   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (BENZO [C][1,2,5] THIADIAZOLE 4 SULFONAMIDO) THIOPHENE 2 CARBOXAMIDO] 5 GUANIDINOPENTANOIC ACID; ANTINEOPLASTIC AGENT; EG 00229; FLUOROURACIL; NEUROPILIN 1; PACLITAXEL; PEPTIDE FRAGMENT; TUFTSIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; CELL MIGRATION; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MUTAGENESIS, SITE-DIRECTED; NEUROPILIN-1; PEPTIDE FRAGMENTS; PHOSPHORYLATION; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949342169     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901755g     Document Type: Article

References (22)

1. Pellet-Many, C.; Frankel, P.; Jia, H.; Zachary, I. Neuropilins: structure, function and role in disease. Biochem. J. 2008, 411, 211-226.
2. Kruger, R. P.; Aurandt, J.; Guan, K. L. Semaphorins command cells to move. Nat. Rev. Mol. Cell Biol. 2005, 6, 789-800.
3. Pan, Q.; Chanthery, Y.; Liang, W. C.; Stawicki, S.; Mak, J.; Rathore, N.; Tong, R. K.; Kowalski, J.; Yee, S. F.; Pacheco, G.; Ross, S.; Cheng, Z.; Le, C. J.; Plowman, G.; Peale, F.; Koch, A. W.; Wu, Y.; Bagri, A.; Tessier-Lavigne, M.; Watts, R. J. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11, 53-67.
4. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450, 1001-1009.
5. Hajduk, P. J.; Huth, J. R.; Tse, C. Predicting protein druggability. Drug Discovery Today 2005, 10, 1675-1682.
6. Lee, C. C.; Kreusch, A.; McMullan, D.; Ng, K.; Spraggon, G. Crystal structure of the human neuropilin-1 bl domain. Structure 2003, 11, 99-108.
7. Vander Kooi, C. W.; Jusino, M. A.; Perman, B.; Neau, D. B.; Bellamy, H. D.; Leahy, D. J. Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 6152-6157.
8. Single letter amino acid nomenclature is used for amino acids in mutations.
9. Jia, H.; Bagherzadeh, A.; Hartzoulakis, B.; Jarvis, A.; Lohr, M.; Shaikh, S.; Aqil, R.; Cheng, L.; Tickner, M.; Esposito, D.; Harris, R.; Driscoll, P. C.; Selwood, D. L.; Zachary, I. C. Characterization of a bicyclic peptide neuropilin-1 (NP-I) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling. J. Biol. Chem. 2006, 281, 13493-13502.
10. Wey, J. S.; Gray, M. J.; Fan, F.; Belcheva, A.; McCarty, M. F.; Stoeltzing, O.; Somcio, R.; Liu, W.; Evans, D. B.; Klagsbrun, M.; Gallick, G. E.; Ellis, L. M. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br. J. Cancer 2005, 93, 233-241.
11. Yu, C.; Friday, B. B.; Lai, J. P.; Yang, L.; Sarkaria, J.; Kay, N. E.; Carter, C. A.; Roberts, L. R.; Kaufmann, S. H.; Adjei, A. A. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. 2006, 5, 2378-2387.
12. Schneider, B. P.; Sledge, G. W., Jr. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? Breast Cancer Res. 2009, 11, 303.
13. Cavanagh, J.; Fairbrother, W. J.; Palmer, A. G.; Rance, M.; Skelton, N. J. Protein NMR Spectroscopy: Principles and Practice, 2nd ed.; Academic Press: Boston, MA, 2007.
14. Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 1995, 6, 277-293.
15. Vranken, W. F.; Boucher, W.; Stevens, T. J.; Fogh, R. H.; Pajon, A.; Llinas, M.; Ulrich, E. L.; Markley, J. L.; Ionides, J.; Laue, E. D. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 2005, 59, 687-696.
16. Pflugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1999, 55, 17181725.
17. CrystalClear: An Integrated Program for the Collection and Processing of Area Detector Data; Rigaku Corporation, 1997.
18. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40, 658-674.
19. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1116-1131.
20. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255.
21. Painter, J.; Merritt, E. A. TLSMD Web server for the generation of multi-group TLS models. J. Appl. Crystallogr. 2006, 39, 109-111.
22. Schuttelkopf, A. W.; van Aalten, D. M. F. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 13551363.